Synapse Biomedical Debuts Diaphragm Pacer, HDE-Cleared To Aid Breathing
This article was originally published in The Gray Sheet
Executive Summary
Synapse Biomedical will pursue expanded approval of its diaphragm pacing system to facilitate breathing in patients with Lou Gehrig's disease after gaining a humanitarian device exemption June 17 for use by ventilator-dependent spinal cord injury patients, according to the company
You may also be interested in...
Synapse Awaits Humanitarian Approval For Diaphragm Pacing System To Treat ALS
Synapse Biomedical expects FDA to issue a humanitarian device exemption within weeks allowing its NeuRX diaphragm pacing system to be marketed to treat patients with amytrophic lateral sclerosis.
Synapse Awaits Humanitarian Approval For Diaphragm Pacing System To Treat ALS
Synapse Biomedical expects FDA to issue a humanitarian device exemption within weeks allowing its NeuRX diaphragm pacing system to be marketed to treat patients with amytrophic lateral sclerosis.
New Products In Brief
SpineSmith Partners’ VisuALIF